- Home
- CHRS vs SRZN Comparison
CHRS vs SRZN Comparison
Compare CHRS & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SRZN
- Stock Information
- Founded
- CHRS 2010
- SRZN 2015
- Country
- CHRS United States
- SRZN United States
- Employees
- CHRS N/A
- SRZN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- CHRS Health Care
- SRZN Health Care
- Exchange
- CHRS Nasdaq
- SRZN Nasdaq
- Market Cap
- CHRS 84.2M
- SRZN 72.8M
- IPO Year
- CHRS 2014
- SRZN N/A
- Fundamental
- Price
- CHRS $0.76
- SRZN $8.97
- Analyst Decision
- CHRS Buy
- SRZN Strong Buy
- Analyst Count
- CHRS 3
- SRZN 2
- Target Price
- CHRS $4.68
- SRZN $38.50
- AVG Volume (30 Days)
- CHRS 1.3M
- SRZN 22.8K
- Earning Date
- CHRS 08-07-2025
- SRZN 08-11-2025
- Dividend Yield
- CHRS N/A
- SRZN N/A
- EPS Growth
- CHRS N/A
- SRZN N/A
- EPS
- CHRS N/A
- SRZN N/A
- Revenue
- CHRS $272,251,000.00
- SRZN $11,638,000.00
- Revenue This Year
- CHRS N/A
- SRZN N/A
- Revenue Next Year
- CHRS $106.56
- SRZN N/A
- P/E Ratio
- CHRS N/A
- SRZN N/A
- Revenue Growth
- CHRS 19.87
- SRZN N/A
- 52 Week Low
- CHRS $0.66
- SRZN $5.90
- 52 Week High
- CHRS $2.43
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- CHRS 46.35
- SRZN 52.19
- Support Level
- CHRS $0.72
- SRZN $8.38
- Resistance Level
- CHRS $0.77
- SRZN $9.88
- Average True Range (ATR)
- CHRS 0.04
- SRZN 0.75
- MACD
- CHRS 0.00
- SRZN -0.02
- Stochastic Oscillator
- CHRS 38.69
- SRZN 53.33
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).